Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines
Open Access
- 10 January 2020
- journal article
- research article
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 140 (4) , 337-343
Abstract
Background: Well characterized human cell lines are needed for preclinical treatment studies of anaplastic thyroid cancer (ATC). Aims/Objectives: The aim was to establish, verify and characterize a panel of ATC cell lines. Material and methods: Cell lines were established from ATC fine-needle aspiration biopsies and characterized genetically and functionally regarding treatment sensitivities. Results: Eight cell lines were established in vitro and the anaplastic thyroid origin was verified. Seven of the cell lines were also grown as xenografts. The cell lines harboured complex karyotypes with modal numbers in hyperdiploid to near-pentaploid range. Five were TP53 mutated and three carried the BRAFV600E mutation. None had rearrangements of RET. For doxorubicin, IC50 ranged from 0.42 to 46 nmol/L and for paclitaxel from 1.6 to 196 nmol/L. Radiation sensitivity varied between 2.6 and 6.3 Gy. Two of the BRAF mutated cell lines displayed high sensitivity to vemurafenib, while the third was similar to the wild-type ones. Conclusions and significance: We describe a series of new ATC cell lines demonstrating large heterogeneity in the response to cytostatic drugs and the BRAF inhibitor vemurafenib. The observations are relevant to future attempts to optimize treatment combinations for ATC.Keywords
This publication has 18 references indexed in Scilit:
- Use of vemurafenib in anaplastic thyroid carcinoma: a case reportCancer Biology & Therapy, 2015
- Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic reviewBMC Surgery, 2013
- BRAF V600E Inhibition in Anaplastic Thyroid CancerNew England Journal of Medicine, 2013
- Detailed Molecular Fingerprinting of Four New Anaplastic Thyroid Carcinoma Cell Lines and Their Use for Verification of RhoB as a Molecular Therapeutic TargetThe Journal of Clinical Endocrinology & Metabolism, 2010
- Centromere-localized breaks indicate the generation of DNA damage by the mitotic spindleProceedings of the National Academy of Sciences, 2010
- Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and MisidentificationThe Journal of Clinical Endocrinology & Metabolism, 2008
- BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemiasLeukemia, 2008
- Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasmsLaboratory Investigation, 2008
- Molecular Cytogenetic Profiles of Novel and Established Human Anaplastic Thyroid Carcinoma ModelsThyroid®, 2007
- Treatment of Anaplastic Thyroid Carcinoma with Paclitaxel: Phase 2 Trial Using Ninety-Six-hour InfusionThyroid®, 2000